BAUDETTE, Minn., Feb. 12, 2020 /PRNewswire/ -- ANI
Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the
launch of Sulfamethoxazole and Trimethoprim Oral Suspension USP 200
mg/40 mg per 5 mL. The current annual market for this product
is approximately $29 million,
according to IQVIA. This launch represents ANI's third generic
product introduction in 2020.
Arthur S. Przybyl, ANI's
President and CEO commented, "This is the twelfth product that ANI
has successfully launched from our library of discontinued NDAs and
ANDAs. This library now includes 118 generic products, 52 of which
can be launched via a CBE-30 or prior approval supplement
filing. We continue to selectively re-commercialize products
from this library that can provide economic value and, when
possible, leverage our internal manufacturing capabilities."
About Sulfamethoxazole and Trimethoprim Oral Suspension USP
200 mg/40 mg per 5 mL
Sulfamethoxazole and Trimethoprim Oral Suspension is indicated
in the treatment and prevention of various infections proven or
strongly suspected to be caused by susceptible bacteria which
include urinary tract infections, acute otitis media, bronchitis,
shigellosis, Pneumocystis jiroveci pneumonia, and traveler's
diarrhea. For more information, including the complete list of
indications and usages, please see the Full Prescribing
Information.
About ANI
ANI Pharmaceuticals, Inc. (the "Company" or "ANI") is an
integrated specialty pharmaceutical company developing,
manufacturing, and marketing branded and generic prescription
pharmaceuticals. The Company's targeted areas of product
development currently include narcotics, oncolytics (anti-cancers),
hormones and steroids, and complex formulations involving extended
release and combination products. For more information, please
visit our website www.anipharmaceuticals.com.
Forward-Looking Statements
To the extent any statements made in this release deal with
information that is not historical, these are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Such statements include, but are not limited
to, statements about price increases, the Company's future
operations, products, financial position, operating results and
prospects , the Company's pipeline or potential markets therefor,
and other statements that are not historical in nature,
particularly those that utilize terminology such as "anticipates,"
"will," "expects," "plans," "potential," "future," "believes,"
"intends," "continue," other words of similar meaning, derivations
of such words and the use of future dates.
Uncertainties and risks may cause the Company's actual results
to be materially different than those expressed in or implied by
such forward-looking statements. Uncertainties and risks include,
but are not limited to, the risk that the Company may face with
respect to importing raw materials; increased competition;
acquisitions; contract manufacturing arrangements; delays or
failure in obtaining product approval from the U.S. Food and Drug
Administration; general business and economic conditions; market
trends; products development; regulatory and other approvals and
marketing.
More detailed information on these and additional factors that
could affect the Company's actual results are described in the
Company's filings with the Securities and Exchange Commission,
including its most recent annual report on Form 10-K and quarterly
reports on Form 10-Q, as well as its proxy statement. All
forward-looking statements in this news release speak only as of
the date of this news release and are based on the Company's
current beliefs, assumptions, and expectations. The Company
undertakes no obligation to update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise.
For more information about ANI, please contact:
Investor Relations
IR@anipharmaceuticals.com
View original
content:http://www.prnewswire.com/news-releases/ani-announces-launch-of-sulfamethoxazole-and-trimethoprim-oral-suspension-usp-200-mg40-mg-per-5-ml-301003525.html
SOURCE ANI Pharmaceuticals, Inc.